Combination therapy of long-acting β agonists and inhaled corticosteroids in the management of chronic asthma

Current Allergy and Asthma Reports

Volumn 5, Issue 2, 2005, Pages 123-129

  Nelson, Harold S ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE; FORMOTEROL; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE;

ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRY POWDER; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; METERED DOSE INHALER; PRACTICE GUIDELINE; REVIEW; SUSTAINED RELEASE PREPARATION;

EID: 14744303633     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-005-0085-x     Document Type: Review

References (41)

1. U.S. Department of Health and Human Services, Public Health Service. National Institutes of Health, National Heart Lung and Blood Institute. Global Initiative for Asthma, updated 2003. http://www.ginasthma.com. Accessed December, 2004.
2. U.S. Department of Health and Human Services, Public Health Service. National Institutes of Health, National Heart Lung and Blood Institute. NAEPP Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma- Update on Selected Topics 2002. NIH Publication No. 02-5075. NHLBI Health Information Network. http://www.nhlbi.nih.gov. Accessed December, 2004.
3. Bensch G, Lapidus RJ, Levine BE, et al.: A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001, 86:19-27.
4. Pearlman DS, Chervinsky P, LaForce C, et al.: A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992, 327:1420-1425.
5. Anderson GP: Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta2-adrenoceptor agonist bronchodilator. Life Sci 1993, 52: 145-2160.
6. Löfdahl C-G: Basic pharmacology of new long-acting sympathomimetics. Lung 1990, 168(Suppl1):18-21.
7. Rabe KF, Jörres R, Nowak D, et al.: Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993, 147:1436-1441.
8. Lazarus SC, Boushey HA, Fahy JV, et al.: Long-acting beta2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomize controlled trail. JAMA 2001, 285:2583-2593.
9. Taylor DR, Drazen JM, Herbison GP: Asthma exacerbations during long term beta-agonist use: influence of beta 2 adrenoceptor polymorphism. Thorax 2000, 55:762-767.
10. Allen DB, Bielory L, Derendorf H, et al.: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003, 112:S1-S40.
11. Kelly HW: Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998, 102:S36-S51.
12. Petersen H, Kullberg A, Edsbacker S, Greiff L: Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo. Pharmacol 2001, 51: 59-163.
13. Martin RJ: Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002, 109: 447-S460.
14. Agertoft L, Pedersen S: A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Tubuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1998, 101:289-290.
15. McFadden ER, Casale TB, Edwards TB, et al.: Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999, 104:46-52.
16. Herjavecz I, Blomqvist P, Serrano A: Efficacy of once- and twice-daily administration of budesonide via Turbubaler as initial therapy in patients with mild persistent asthma. Respir Med 1999, 93:230-235.
17. Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ: Inhaled fluticasone propionate by Diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003, 124:1584-1593.
18. Greening AP, Ind PW, Northfield M, Shaw G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994, 344:219-224.
19. McIver RA, Pizzichini E, Turner MO, et al.: Potential masking effect of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998, 158:924-930.
20. Pauwels RA, Löfdahl C-G, Postma DS, et al.: Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997, 337:1405-1411.
21. Shrewsbury S, Pyke S, Britton M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000, 320:1368-1373.
22. Eickelberg O, Roth M, Lors R, et al.: Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999, 274: 005-1010.
23. Nelson HS, Chapman KR, Pyke SD, et al.: Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003, 112:29-36.
24. Goldsmith DR, Keating GM: Budesonide/formoterol: a review of its use in asthma. Drugs 2004, 64:1597-1618.
25. Advair Diskus: Package insert. Research Triangle Park, NC: GlaxoSmithKline. 2004.
26. Palmqvist M, Arvidsson P, Beckman O, et al.: Onset of bronchodilation of budesonide/formoterol vs salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001, 14:29-34.
27. Aalbers R, Backer V, Kava TK, et al.: Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004, 20:225-240.
28. Stoloff SW, Stempel DA, Meyer J, et al.: Improved refill persistence with fluticasone dipropionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004, 113:245-251.
29. Davies B, Brooks G, Devoy M: The efficacy and safety of salmeterol compared to theophylline: a meta-analysis of nine controlled studies. Respir Med 1998, 92:556-563.
30. Fish JE, Israel E, Murray JJ, et al.: Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001, 120:423-430.
31. Bjermer L, Bustard H, Bouquet J, et al.: Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbations in adults: one year, double blind, randomised, comparative trial. BMJ 2003, 327:891-896.
32. Ilowite J, Webb R, Friedman B, et al.: Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double blind, multicenter study. Ann Allergy Asthma Immunol 2004, 92:641-648.
33. Nelson HS, Busse WW, Kerwin E, et al.: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000, 106:1088-1095.
34. Ringdal N, Eliraz A, Pruzinec P, et al.: The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003, 97: 34-241.
35. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004, 59:469-478.
36. Bateman ED, Boushey HA, Bousquet J, et al.: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004, 170: 36-844.
37. Buhl R, Creemers JPHM, Vondra V, et al.: Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003, 97:323-330.
38. FitzGerald JM, Sears MR, Boulet L-P, et al.: Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicenter Canadian study. Can Respir J 2003, 10:427-434.
39. Ind PW, Haughney J, Price D, et al.: Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004, 98:464-475.
40. Boonsawat W, Charoenratanakul S, Pothirat C, et al.: Formoterol (Oxis) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir J Med 2003, 97:1067-1074.
41. Pauwels RA, Sears MR, Campbell M, et al.: Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Resp J 2003, 22:787-794.